Drug
Nanoliposomal Irinotecan
Nanoliposomal Irinotecan: highest development phase Phase 1, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| nanoliposomal irinotecan NCT02022644 | Phase 1 | High Grade Glioma |
Latest
No recent events.
Follow Nanoliposomal Irinotecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.